NovaBay Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: Emeryville CA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2008
NCT00781339
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

NovaBay Pharmaceuticals, Inc. | NovaBay Pharmaceuticals / kkrantz@novabaypharma.com

Active Ingredients

Drugs in Phase 3 Trials (1)

auriclosene (7 trials)

Drugs in Phase 2 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacteriuria (Phase 2)

Conjunctivitis (Phase 2)

Conjunctivitis, Bacterial (Phase 2)

Conjunctivitis, Inclusion (Phase 2)

Impetigo (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 2